Funding for this research was provided by:
PhRMA
Article History
Accepted: 27 May 2021
First Online: 19 June 2021
Change Date: 26 August 2022
Change Type: Update
Change Details: A peer-reviewed video was retrospectively added to this publication.
Declarations
:
: The investigative work and writing activities to develop this review are conducted as PhRMA Japan MAC WG1 members' activities, and there is no special funding per se. The editorial fees and the article processing charge were funded by PhRMA, a non-profit organization.
: KH is an employee of Amgen K.K. and was an employee of Amgen Astellas BioPharma K.K. at the time of planning and writing this manuscript and a stockholder of Amgen Inc. AB is an employee and stockholder of Eli Lilly and Company Limited. YM is an employee of Bristol Myers Squibb K.K. and was an employee of Janssen Pharmaceutical K.K. and a stockholder of Johnson & Johnson at the time of planning and writing this paper.
: Data sharing is not applicable to this article as no datasets were generated or analyzed.
: Not applicable.
: All authors contributed to the planning and critical review of the manuscript. KH and AB drafted the manuscript. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for the manuscript before submission and for this version to be published.